Literature DB >> 12412571

[High frequency of precancerous lesions of gastric cancer associated with Helicobacter pylori and response to treatment, in Chiapas, Mexico].

Alejandro Mohar1, Catherine Ley, Jeannette Guarner, Roberto Herrera-Goepfert, Luz Sánchez, David Halperin, Julie Parsonnet.   

Abstract

Stomach cancer is the second cause of death in Mexico in patients with malignant tumors. This disease represents a public health problem. A strong association has been described between chronic infection with Helicobacter pylori and gastric cancer. This malignancy is preceded by a series of preneoplastic conditions, including chronic atrophic gastritis (CAG), intestinal metaplasia (IM), and dysplasia. The objective of this study was to establish the prevalence of preneoplastic conditions associated with infection of Helicobacter pylori in the state of Chiapas and its eradication with antibiotics. Persons infected with Helicobacter pylori and with CAG were identified by serology against CagA protein and serologic levels of gastrin. An endoscopy with biopsy was performed at the beginning of the study, and at 6 weeks and 1 year thereafter. A total of 281 people were enrolled and randomly assigned to treatment or placebo group. CAG was found in 59%, IM in 51%, and dysplasia in 13%. In intent-to-treat and per-protocol analysis, Helicobacter pylori was eliminated in 70 and 76%, respectively. These results indicate high frequency of preneoplastic conditions associated with Helicobacter pylori and an excellent eradication rate. They also offer a possible alternative for preventing gastric cancer.

Entities:  

Mesh:

Year:  2002        PMID: 12412571

Source DB:  PubMed          Journal:  Gac Med Mex        ISSN: 0016-3813            Impact factor:   0.302


  1 in total

1.  A Data Preparation Methodology in Data Mining Applied to Mortality Population Databases.

Authors:  Joaquín Pérez; Emmanuel Iturbide; Víctor Olivares; Miguel Hidalgo; Alicia Martínez; Nelva Almanza
Journal:  J Med Syst       Date:  2015-09-18       Impact factor: 4.460

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.